Literature DB >> 30192413

Chemical space of Escherichia coli dihydrofolate reductase inhibitors: New approaches for discovering novel drugs for old bugs.

Bharath Srinivasan1, Sam Tonddast-Navaei1, Ambrish Roy1, Hongyi Zhou1, Jeffrey Skolnick1.   

Abstract

Escherichia coli Dihydrofolate reductase is an important enzyme that is essential for the survival of the Gram-negative microorganism. Inhibitors designed against this enzyme have demonstrated application as antibiotics. However, either because of poor bioavailability of the small-molecules resulting from their inability to cross the double membrane in Gram-negative bacteria or because the microorganism develops resistance to the antibiotics by mutating the DHFR target, discovery of new antibiotics against the enzyme is mandatory to overcome drug-resistance. This review summarizes the field of DHFR inhibition with special focus on recent efforts to effectively interface computational and experimental efforts to discover novel classes of inhibitors that target allosteric and active-sites in drug-resistant variants of EcDHFR.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Escherichia coli; dihydrofolate reductase; drug resistance; quantitative structure-activity relationship; virtual ligand screening

Mesh:

Substances:

Year:  2018        PMID: 30192413      PMCID: PMC6370515          DOI: 10.1002/med.21538

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  130 in total

1.  Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy.

Authors:  Jon A Erickson; Mehran Jalaie; Daniel H Robertson; Richard A Lewis; Michal Vieth
Journal:  J Med Chem       Date:  2004-01-01       Impact factor: 7.446

Review 2.  From magic bullets to designed multiple ligands.

Authors:  Richard Morphy; Corinne Kay; Zoran Rankovic
Journal:  Drug Discov Today       Date:  2004-08-01       Impact factor: 7.851

Review 3.  Fragment informatics and computational fragment-based drug design: an overview and update.

Authors:  Chunquan Sheng; Wannian Zhang
Journal:  Med Res Rev       Date:  2012-03-19       Impact factor: 12.944

4.  Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.

Authors:  Katherine H Luepke; Katie J Suda; Helen Boucher; Rene L Russo; Michael W Bonney; Timothy D Hunt; John F Mohr
Journal:  Pharmacotherapy       Date:  2016-12-27       Impact factor: 4.705

5.  Learning from our mistakes: the 'unknown knowns' in fragment screening.

Authors:  Ben J Davis; Daniel A Erlanson
Journal:  Bioorg Med Chem Lett       Date:  2013-03-18       Impact factor: 2.823

6.  Biophysical principles predict fitness landscapes of drug resistance.

Authors:  João V Rodrigues; Shimon Bershtein; Anna Li; Elena R Lozovsky; Daniel L Hartl; Eugene I Shakhnovich
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

Review 7.  Mechanisms of action and resistance of older and newer fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

Review 8.  Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.

Authors:  Leah N Makley; Jason E Gestwicki
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

9.  Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda.

Authors:  Caroline Lynch; Richard Pearce; Hirva Pota; Jonathan Cox; Tarekegn A Abeku; John Rwakimari; Inbarani Naidoo; James Tibenderana; Cally Roper
Journal:  J Infect Dis       Date:  2008-06-01       Impact factor: 5.226

10.  Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?

Authors:  Martin Exner; Sanjay Bhattacharya; Bärbel Christiansen; Jürgen Gebel; Peter Goroncy-Bermes; Philippe Hartemann; Peter Heeg; Carola Ilschner; Axel Kramer; Elaine Larson; Wolfgang Merkens; Martin Mielke; Peter Oltmanns; Birgit Ross; Manfred Rotter; Ricarda Maria Schmithausen; Hans-Günther Sonntag; Matthias Trautmann
Journal:  GMS Hyg Infect Control       Date:  2017-04-10
View more
  2 in total

1.  Cinnamomum zeylanicum Extract and its Bioactive Component Cinnamaldehyde Show Anti-Tumor Effects via Inhibition of Multiple Cellular Pathways.

Authors:  Sadhna Aggarwal; Kanchan Bhadana; Baldeep Singh; Meenakshi Rawat; Taj Mohammad; Lamya Ahmed Al-Keridis; Nawaf Alshammari; Md Imtaiyaz Hassan; Satya N Das
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 2.  Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.

Authors:  Agnieszka Wróbel; Karolina Arciszewska; Dawid Maliszewski; Danuta Drozdowska
Journal:  J Antibiot (Tokyo)       Date:  2019-10-02       Impact factor: 2.649

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.